Iovance Biotherapeutics, Inc.IOVANASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank14
Studio
Year-over-Year Change

Cash generated from core business operations

Latest
$-302.41M
↓ 43% vs avg
Percentile
P14
Within normal range
Streak
2 yr
Consecutive growthContracting
Average
$-211.46M
Historical baseline
PeriodValueYoY Change
TTM$-302.41M+14.3%
2024$-352.98M+2.4%
2023$-361.82M-23.6%
2022$-292.76M-28.4%
2021$-227.94M-11.1%
2020$-205.13M-29.1%
2019$-158.89M-56.9%
2018$-101.25M-28.6%
2017$-78.71M-140.9%
2016$-32.67M-